Skip to main content
. 2015 Jan 8;172(5):1379–1394. doi: 10.1111/bph.13016

Figure 6.

Figure 6

Effects of tamoxifen, raloxifene, toremifene and lovastatin on DiI-LDL uptake by MOLT-4 cells, lymphocytes and HepG2 cells. (A) MOLT-4 cells were treated with DiI-LDL and vehicle, 5 μM tamoxifen (TAM), raloxifene (RAL) or toremifene (TOR), 1 μM lovastatin (LOV) or the combinations of these drugs for 24 h as indicated. Data (mean ± SEM) correspond to five independent experiments and are expressed as % of the corresponding condition without any drug added. (B) Lymphocytes from 10 male donors were treated as indicated for MOLT-4 cells. Data (mean ± SEM) are expressed as % of the condition without any drug added of the same cell preparation. (C) HepG2 cells were treated as indicated for MOLT-4 cells and lymphocytes. Data (mean ± SEM) correspond to five independent experiments and are expressed as % of the corresponding condition without any drug added. Statistical analyses were performed by two-way RM anova and post hoc by the Student–Newman–Keuls test. ●●P < 0.01, ●●●P < 0.001 between presence and absence of LOV; *P < 0.05, ***P < 0.001 versus control; ##P < 0.01, ###P < 0.001 versus RAL; §§P < 0.01 versus TOR. For simplicity, the statistical differences between the conditions within the presence of LOV were omitted.